Antidepressants and Suicidality

Psychiatric Clinics of North America

Volumn 39, Issue 3, 2016, Pages 503-512

  Brent, David A ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Adolescents; Antidepressant; Clinical trials; Depression; Suicidal events; Suicide; Young adults

Indexed keywords

ANTIDEPRESSANT AGENT; SEROTONIN UPTAKE INHIBITOR;

ALCOHOL ABUSE; AUTOMUTILATION; DRUG USE; FAMILY CONFLICT; HIGH RISK POPULATION; HUMAN; META ANALYSIS (TOPIC); PATIENT EDUCATION; PATIENT SAFETY; PHARMACOEPIDEMIOLOGY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; SUBSTANCE USE; SUICIDAL BEHAVIOR; SUICIDAL IDEATION; SUICIDE ATTEMPT; TREATMENT RESPONSE; ADOLESCENT; ADULT; META ANALYSIS;

ADOLESCENT; ADULT; ANTIDEPRESSIVE AGENTS; HUMANS; SUICIDAL IDEATION; SUICIDE, ATTEMPTED;

EID: 84977557860     PISSN: 0193953X     EISSN: 15583147     Source Type: Journal    
DOI: 10.1016/j.psc.2016.04.002     Document Type: Review

References (49)

1. 1 Posner, K., Oquendo, M.A., Gould, M., et al. Columbia classification algorithm of suicide assessment (C-CASA): classification of suicidal events in the FDA's pediatric suicidal risk analysis of antidepressants. Am J Psychiatry 164:7 (2007), 1035–1043.
2. 2 Hammad, T.A., Laughren, T., Racoosin, J., Suicidality in pediatric patients treated with antidepressant drugs. Arch Gen Psychiatry 63:3 (2006), 332–339.
3. 3 Stone, M., Laughren, T., Jones, M.L., et al. Risk of suicidality in clinical trials of antidepressants in adults: analysis of proprietary data submitted to US Food and Drug Administration. BMJ, 339, 2009, b2880.
4. 4 Bridge, J.A., Iyengar, S., Salary, C.B., et al. Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials. JAMA 297:15 (2007), 1683–1696.
5. 5 Hetrick, S.E., McKenzie, J.E., Cox, G.R., et al. Newer generation antidepressants for depressive disorders in children and adolescents. Cochrane Database Syst Rev(11), 2012 CD004851.
6. 6 Berk, M., Dodd, S., Are treatment emergent suicidality and decreased response to antidepressants in younger patients due to bipolar disorder being misdiagnosed as unipolar depression?. Med Hypotheses 65:1 (2005), 39–43.
7. 7 Martin, A., Young, C., Leckman, J.F., et al. Age effects on antidepressant-induced manic conversion. Arch Pediatr Adolesc Med 158:8 (2004), 773–780.
8. 8 Offidani, E., Fava, G.A., Tomba, E., et al. Excessive mood elevation and behavioral activation with antidepressant treatment of juvenile depressive and anxiety disorders: a systematic review. Psychother Psychosom 82:3 (2013), 132–141.
9. 9 Casey, B.J., Jones, R.M., Levita, L., et al. The storm and stress of adolescence: insights from human imaging and mouse genetics. Dev Psychobiol 52:3 (2010), 225–235.
10. 10 Tauscher, J., Verhoeff, N.P., Christensen, B.K., et al. Serotonin 5-HT1A receptor binding potential declines with age as measured by [11C]WAY-100635 and PET. Neuropsychopharmacology 24:5 (2001), 522–530.
11. 11 Moses-Kolko, E.L., Price, J.C., Shah, N., et al. Age, sex, and reproductive hormone effects on brain serotonin-1A and serotonin-2A receptor binding in a healthy population. Neuropsychopharmacology 36:13 (2011), 2729–2740.
12. 12 Sullivan, G.M., Oquendo, M.A., Milak, M., et al. Positron emission tomography quantification of serotonin(1A) receptor binding in suicide attempters with major depressive disorder. JAMA Psychiatry 72:2 (2015), 169–178.
13. 13 Miller, J.M., Hesselgrave, N., Ogden, R.T., et al. Brain serotonin 1A receptor binding as a predictor of treatment outcome in major depressive disorder. Biol Psychiatry 74:10 (2013), 760–767.
14. 14 Oquendo, M.A., Russo, S.A., Underwood, M.D., et al. Higher postmortem prefrontal 5-HT2A receptor binding correlates with lifetime aggression in suicide. Biol Psychiatry 59:3 (2006), 235–243.
15. 15 McGirr, A., Renaud, J., Bureau, A., et al. Impulsive-aggressive behaviours and completed suicide across the life cycle: a predisposition for younger age of suicide. Psychol Med 38:3 (2008), 407–417.
16. 16 Axelson, D.A., Perel, J.M., Birmaher, B., et al. Sertraline pharmacokinetics and dynamics in adolescents. J Am Acad Child Adolesc Psychiatry 41:9 (2002), 1037–1044.
17. 17 Sakolsky, D.J., Perel, J.M., Emslie, G.J., et al. Antidepressant exposure as a predictor of clinical outcomes in the Treatment of Resistant Depression in Adolescents (TORDIA) study. J Clin Psychopharmacol 31:1 (2011), 92–97.
18. 18 Smith, E.G., Association between antidepressant half-life and the risk of suicidal ideation or behavior among children and adolescents: confirmatory analysis and research implications. J Affect Disord 114:1–3 (2009), 143–148.
19. 19 Gibbons, R.D., Brown, C.H., Hur, K., et al. Suicidal thoughts and behavior with antidepressant treatment: reanalysis of the randomized placebo-controlled studies of fluoxetine and venlafaxine. Arch Gen Psychiatry 69:6 (2012), 580–587.
20. 20 Wichniak, A., Wierzbicka, A., Jernajczyk, W., Sleep and antidepressant treatment. Curr Pharm Des 18:36 (2012), 5802–5817.
21. 21 Pigeon, W.R., Pinquart, M., Conner, K., Meta-analysis of sleep disturbance and suicidal thoughts and behaviors. J Clin Psychiatry 73:9 (2012), e1160–1167.
22. 22 Brent, D.A., Emslie, G.J., Clarke, G.N., et al. Predictors of spontaneous and systematically assessed suicidal adverse events in the treatment of SSRI-resistant depression in adolescents (TORDIA) study. Am J Psychiatry 166:4 (2009), 418–426.
23. 23 Mann, J.J., Emslie, G., Baldessarini, R.J., et al. ACNP Task Force report on SSRIs and suicidal behavior in youth. Neuropsychopharmacology 31:3 (2006), 473–492.
24. 24 Ludwig, J., Marcotte, D.E., Anti-depressants, suicide, and drug regulation. J Policy Anal Manage 24:2 (2005), 249–272.
25. 25 Gibbons, R.D., Hur, K., Bhaumik, D.K., et al. The relationship between antidepressant medication use and rate of suicide. Arch Gen Psychiatry 62:2 (2005), 165–172.
26. 26 Olfson, M., Shaffer, D., Marcus, S.C., et al. Relationship between antidepressant medication treatment and suicide in adolescents. Arch Gen Psychiatry 60:10 (2003), 978–982.
27. 27 Valuck, R.J., Libby, A.M., Sills, M.R., et al. Antidepressant treatment and risk of suicide attempt by adolescents with major depressive disorder: a propensity-adjusted retrospective cohort study. CNS Drugs 18:15 (2004), 1119–1132.
28. 28 Tiihonen, J., Lonnqvist, J., Wahlbeck, K., et al. Antidepressants and the risk of suicide, attempted suicide, and overall mortality in a nationwide cohort. Arch Gen Psychiatry 63:12 (2006), 1358–1367.
29. 29 Wijlaars, L.P., Nazareth, I., Whitaker, H.J., et al. Suicide-related events in young people following prescription of SSRIs and other antidepressants: a self-controlled case series analysis. BMJ Open, 3(9), 2013, e003247.
30. 30 Simon, G.E., Savarino, J., Operskalski, B., et al. Suicide risk during antidepressant treatment. Am J Psychiatry 163:1 (2006), 41–47.
31. 31 Gibbons, R.D., Coca Perraillon, M., Hur, K., et al. Antidepressant treatment and suicide attempts and self-inflicted injury in children and adolescents. Pharmacoepidemiol Drug Saf 24:2 (2015), 208–214.
32. 32 Olfson, M., Marcus, S.C., Shaffer, D., Antidepressant drug therapy and suicide in severely depressed children and adults: a case-control study. Arch Gen Psychiatry 63:8 (2006), 865–872.
33. 33 Leon, A.C., Marzuk, P.M., Tardiff, K., et al. Paroxetine, other antidepressants, and youth suicide in New York City: 1993 through 1998. J Clin Psychiatry 65:7 (2004), 915–918.
34. 34 Courtet, P., Lopez-Castroman, J., Jaussent, I., et al. Antidepressant dosage and suicidal ideation. JAMA Intern Med 174:11 (2014), 1863–1865.
35. 35 Coupland, C., Hill, T., Morriss, R., et al. Antidepressant use and risk of suicide and attempted suicide or self-harm in people aged 20 to 64: cohort study using a primary care database. BMJ, 350, 2015, h517.
36. 36 Gibbons, R.D., Brown, C.H., Hur, K., et al. Early evidence on the effects of regulators’ suicidality warnings on SSRI prescriptions and suicide in children and adolescents. Am J Psychiatry 164:9 (2007), 1356–1363.
37. 37 Libby, A.M., Orton, H.D., Valuck, R.J., Persisting decline in depression treatment after FDA warnings. Arch Gen Psychiatry 66:6 (2009), 633–639.
38. 38 Katz, L.Y., Kozyrskyj, A.L., Prior, H.J., et al. Effect of regulatory warnings on antidepressant prescription rates, use of health services and outcomes among children, adolescents and young adults. CMAJ 178:8 (2008), 1005–1011.
39. 39 Wheeler, B.W., Gunnell, D., Metcalfe, C., et al. The population impact on incidence of suicide and non-fatal self-harm of regulatory action against the use of selective serotonin reuptake inhibitors in under 18s in the United Kingdom: ecological study. BMJ 336:7643 (2008), 542–545.
40. 40 Wilkinson, P., Kelvin, R., Roberts, C., et al. Clinical and psychosocial predictors of suicide attempts and nonsuicidal self-injury in the adolescent depression antidepressants and psychotherapy trial (ADAPT). Am J Psychiatry 168:5 (2011), 495–501.
41. 41 Asarnow, J.R., Porta, G., Spirito, A., et al. Suicide attempts and nonsuicidal self-injury in the treatment of resistant depression in adolescents: findings from the TORDIA study. J Am Acad Child Adolesc Psychiatry 50:8 (2011), 772–781.
42. 42 March, J.S., Silva, S., Petrycki, S., et al. The treatment for adolescents with depression study (TADS): long-term effectiveness and safety outcomes. Arch Gen Psychiatry 64:10 (2007), 1132–1143.
43. 43 Miller, M., Swanson, S.A., Azrael, D., et al. Antidepressant dose, age, and the risk of deliberate self-harm. JAMA Intern Med 174:6 (2014), 899–909.
44. 44 Schneeweiss, S., Patrick, A.R., Solomon, D.H., et al. Variation in the risk of suicide attempts and completed suicides by antidepressant agent in adults: a propensity score-adjusted analysis of 9 years’ data. Arch Gen Psychiatry 67:5 (2010), 497–506.
45. 45 American Academy of Child & Adolescent Psychiatry. Information for patients and their families. Available at: http://www.aacap.org/AACAP/Resources_for_Primary_Care/Information_for_Patients_and_Their_Families/Home.aspx?hkey=bce12396-b276-4fed-8430-ca8628eb1a2b. Accessed March 1, 2016.
46. 46 Woldu, H., Porta, G., Goldstein, T., et al. Pharmacokinetically and clinician-determined adherence to an antidepressant regimen and clinical outcome in the TORDIA trial. J Am Acad Child Adolesc Psychiatry 50:5 (2011), 490–498.
47. 47 Maalouf, F.T., Atwi, M., Brent, D.A., Treatment-resistant depression in adolescents: review and updates on clinical management. Depress Anxiety 28:11 (2011), 946–954.
48. 48 Stanley, B., Brown, G., Brent, D.A., et al. Cognitive-behavioral therapy for suicide prevention (CBT-SP): treatment model, feasibility, and acceptability. J Am Acad Child Adolesc Psychiatry 48:10 (2009), 1005–1013.
49. 49 March, J., Silva, S., Petrycki, S., et al. Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial. JAMA 292:7 (2004), 807–820.